China Isotope & Radiation (HKSE:01763) Accounts Payable & Accrued Expense : HK$3,639 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Accounts Payable & Accrued Expense?

China Isotope & Radiation's quarterly accounts payable & accrued expense declined from Dec. 2022 (HK$3,635 Mil) to Jun. 2023 (HK$653 Mil) but then increased from Jun. 2023 (HK$653 Mil) to Dec. 2023 (HK$3,639 Mil).

China Isotope & Radiation's annual accounts payable & accrued expense increased from Dec. 2021 (HK$509 Mil) to Dec. 2022 (HK$3,635 Mil) and increased from Dec. 2022 (HK$3,635 Mil) to Dec. 2023 (HK$3,639 Mil).

China Isotope & Radiation Accounts Payable & Accrued Expense Historical Data

The historical data trend for China Isotope & Radiation's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Accounts Payable & Accrued Expense Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2,620.75

2,729.47

509.00

3,634.58

3,638.64

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial											509.00	657.38	3,634.58	653.45	3,638.64

China Isotope & Radiation Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines